In the field of innovative vaccine research and development, the technological innovation of the vaccine itself also includes the innovation of the delivery system. Adenovirus, lentivirus, poxvirus and other carriers can not only transport nucleic acid substances stably, but also produce a strong and sustained immune response.Therefore, the clinical detection and evaluation of innovative vaccines are more abundant than ever before.KingMyLab Pharmaceutical has accumulated rich experience in the field of vaccine clinical trials.Since 2014, it has undertaken a number of domestic and foreign clinical research projects such as HPV, COVID-19 vaccine and RSV. By 2022, the company has supported more than 50% of the domestic phase III clinical trials of HPV vaccine, helping the approval and listing of WoZeHui ®, the first innovative multi-center clinical trial vaccine carried out in China's disease prevention and control system. In the vaccine project, the multi-omics platform of KingMed provides strong support for the development of vaccines. Combined with real-world epidemiological data, we provides customers with one-stop solutions for safety evaluation, immunogenicity analysis, clinical endpoints and other related tests.